Permeability to Skin Tissue and Clinical Efficacy in Bacterial Skin Infections on Ciprofloxacin

Abstract

Permeability to skin tissue in healthy volunteers and clinical efficacy of ciprofloxacin (CPFX) in bacterial skin infections were studied. Skin tissue and serum concentrations of CPFX at 2 hours after the oral single dose of 200mg of CPFX were determinated by high-performance liquid chromatography. The results were 0.99jUg/ml in serum and 1.18 fig/g in skin tissue, and the ratio of skin tissue and serum concentration was 1.12. One hundred and fifty mg of tosufloxacin (TFLX) was administered at the same time as the comparative drug and the results were 0.49g/ml, 0.34fig/g and 0.57 respectively. Skin tissue and serum concentrations of CPFX were significantly higher than these of TFLX. Thirty patients were enrolled in this clinical trial to evaluate the efficacy of oral CPFX. These patients were suffering from various bacterial skin infections including infectious atheroma (7 cases), whitlow (4 cases), folliculitis (3 cases) and the others. Before the treatment, culture specimens from the lesions were obtained, and Staphylococcus aureus were isolated in 12 cases. The MICs of CPFX were 0.1-0.39jWg/ml against these 12 Staphylococcus aureus strains. The dose of CPFX were 600mg/day in 29 patients and 800mg/day in a patient. The durations of administration were 5-14 days in 29 patients. Results obtained were following; marked improvement in 15 cases, moderate improvement in 8 cases, slight improvement in 3 cases and the efficacy rate was 85.2%. Any clinical adverse reactions were not seen in all patients. These findings of our studies support that CPFX is effective and safe for the treatment of bacterial skin infections. © 1994, Meeting of Osaka Dermatological Association. All rights reserved.